STERIS (NYSE:STE) Rating Reiterated by Piper Sandler

STERIS (NYSE:STE - Get Free Report)'s stock had its "neutral" rating reiterated by research analysts at Piper Sandler in a research report issued on Friday, Benzinga reports. They currently have a $225.00 target price on the medical equipment provider's stock, up from their prior target price of $220.00. Piper Sandler's price objective would suggest a potential downside of 2.74% from the company's current price.

Other analysts have also issued research reports about the company. StockNews.com lowered STERIS from a "buy" rating to a "hold" rating in a research note on Friday, May 3rd. JMP Securities reissued a "market outperform" rating and issued a $265.00 price target on shares of STERIS in a report on Thursday. KeyCorp assumed coverage on shares of STERIS in a research note on Tuesday, February 6th. They set an "overweight" rating and a $253.00 price objective for the company. Needham & Company LLC reaffirmed a "hold" rating on shares of STERIS in a research report on Friday. Finally, Stephens reissued an "overweight" rating and set a $250.00 target price on shares of STERIS in a research note on Friday, February 9th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $241.60.

STERIS Stock Performance

Shares of STERIS stock traded up $5.34 during trading hours on Friday, hitting $231.33. 862,971 shares of the company's stock traded hands, compared to its average volume of 479,375. The company has a fifty day simple moving average of $217.02 and a 200-day simple moving average of $216.04. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.43 and a quick ratio of 1.49. The stock has a market capitalization of $22.86 billion, a price-to-earnings ratio of 39.58 and a beta of 0.81. STERIS has a 12-month low of $195.47 and a 12-month high of $254.00.

STERIS (NYSE:STE - Get Free Report) last issued its earnings results on Wednesday, May 8th. The medical equipment provider reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.41 by $0.17. The business had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.41 billion. STERIS had a return on equity of 13.67% and a net margin of 10.48%. STERIS's revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.30 earnings per share. Equities research analysts anticipate that STERIS will post 8.67 EPS for the current fiscal year.

Institutional Investors Weigh In On STERIS

Several institutional investors have recently modified their holdings of STE. Millburn Ridgefield Corp bought a new position in shares of STERIS during the third quarter valued at approximately $25,000. Catalyst Capital Advisors LLC purchased a new stake in STERIS in the third quarter worth $25,000. First Personal Financial Services purchased a new stake in shares of STERIS during the first quarter valued at $25,000. J.Safra Asset Management Corp increased its stake in STERIS by 77.9% in the 1st quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider's stock worth $27,000 after buying an additional 53 shares during the period. Finally, Quent Capital LLC lifted its holdings in STERIS by 112.7% during the 1st quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider's stock valued at $30,000 after buying an additional 71 shares in the last quarter. 94.69% of the stock is owned by institutional investors.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.